Equashield Reports Surging Growth In Both U.S. And International Markets, 40 Percent Year-over-year Increase In Revenues

PR72002

PORT WASHINGTON, New York, January 24, /PRNewswire=KYODO JBN/--

Company expects growth to accelerate in 2018, due to worker safety regulation,

increased market understanding of advantages of Equashield truly-closed

system   

Equashield (http://www.equashield.com), a leading provider of Closed System

Transfer Devices (CSTDs) for hazardous drugs, announced today its 2017 growth

results, including a 42 percent year-over-year increase in revenues. In

addition, the company projects a higher growth rate in 2018, driven in part by

the company's newly introduced hazardous drug compounding robot.

Equashield's customer base continues to expand, with 60 percent of new

customers transitioning away from competing systems to Equashield's CSTD, while

40 percent of customers are introducing CSTDs into their hazardous drug

handling practice for the first time.

"CSTDs have now become a standard of safety, with pharmacists no longer asking

if they should use a CSTD. Instead, they are focused solely on when they will

implement a closed system," said Marino Kriheli, Co-Founder of Equashield. "The

USP 800 mandate, which requires the use of closed systems in the administration

of hazardous drugs, and strongly recommends them in the compounding process,

has driven official acceptance of CSTDs as a standard in both pharmacy and

nursing, making them a must-have."

At the end of 2017, over 1,000 sites were using Equashield's closed system,

including major hospital systems and NCI and NCCN facilities dedicated to

cancer care. Equashield also expanded into new markets internationally in 2017,

including Singapore, Hong Kong, Greece, Portugal, Spain, Germany, and the

United Kingdom.  

"We continue to see market share in the United States moving towards increased

adoption of the Equashield system. Since 2015, Equashield has tripled its

marketshare, said Ronak Kadakia, Director of Marketing and Business

Development, Equashield LLC. "Since our product is clinically driven and based

on scientifically proven safety and efficacy, large academic medical centers

and clinically focused institutions have transitioned to utilizing mechanically

closed systems, such as Equashield."

"ROW growth is strong, as evidenced by penetrating seven new markets

internationally in 2017," said Adi Shor, VP Sales ROW. "As we enter 2018, we

are already signing new exclusive distribution agreements with partners around

the world, as CSTDs gain greater visibility and acceptance as standard practice

for oncology treatment."

About Equashield

Equashield is a leading provider of a full range of manual and automated

solutions to hospitals for the compounding and administration of hazardous

drugs. Equashield's product suite includes EQUASHIELD II, its flagship Closed

System Transfer Device (CSTD), and EQUASHIELD(R) Pro, the first ever closed

system drug compounding robot. Equashield's CSTD is clinically-proven to

protect healthcare professionals from hazardous drug exposure.  The globally

awarded EQUASHIELD(R) II covers more routes of exposure than alternative

systems by preventing contamination of syringe plungers and drug residuals on

connector surfaces, as well as exposure to drug vapors. Studies have shown

Equashield's CSTD to be faster to deploy and easier to use than competing

systems, and the system has passed the proposed 2015 alcohol vapor containment

protocol from NIOSH, confirming that it can contain the harshest vapors &

emissions. EQUASHIELD is in use by hundreds of hospitals and clinics around the

world, and has been both cleared by the FDA under the ONB product code, and

substantiated in FDA-cleared labeling as preventing microbial ingress for up to

seven days.

Follow Equashield on LinkedIn, Twitter and Facebook.

For more information: http://www.equashield.com

Media Contact:

Finn Partners for Equashield

Nicole Grubner

nicole.grubner@finnpartners.com

@nicolegrubner

+1-929-222-8011

SOURCE: Equashield